ADMA ADMA BIOLOGICS, INC. Insider Trading

Director Jerrold B Grossman buys 6,400 ADMA shares at $7.91; stock down -64.6% from 52-week high of $22.37

Jerrold B Grossman, a director, purchased 6,400 shares at $7.91 on 2026-05-27, increasing his holdings to 520,284 shares. This occurs as ADMA trades at $7.93, representing a significant decline of -64.6% from the 52-week high of $22.37 and a 90-day decline of -49.1%. Grossman's cross-ticker track record shows mixed results: his 3 prior buys averaged -1.1% returns over 90 days with a 0.00% win rate, while his same-ticker history at ADMA includes two recent purchases (2026-05-12 and 2026-05-11) that each returned -1.1% over 90 days. The company's fundamentals remain solid with revenue of $114,493,000.00, net income of $45,328,000.00, a P/E of 11.17, and annual revenue growth of +19.6%, but the substantial stock price decline raises questions about market confidence despite operational performance.

ADMA Biologics director Grossman buys 12,500 shares in 3rd open-market purchase at ADMA in under 3 years, adding to position near 52-week lows

Director Jerrold B. Grossman made his third open-market purchase of ADMA Biologics shares in the 36-month window, acquiring 12,500 shares and expanding his direct stake from roughly 501,000 to nearly 514,000 shares. The stock is trading sharply below its 52-week high and near its 52-week low, having declined substantially over both the past month and the past three months — meaning Grossman is stepping into meaningful recent weakness. ADMA Biologics is a profitable company with growing annual revenue, and its valuation appears modest relative to its earnings, which provides some fundamental backdrop for a director's open-market commitment. Grossman's same-ticker track record shows mixed results: his one evaluated prior buy at this stock was well-timed at both the 30-day and 90-day marks, while his one evaluated prior sell was poorly timed — the stock rose significantly in the months that followed. Taken together, the director is a repeat open-market buyer at this company whose single evaluated prior buy produced a positive outcome, though his selling record at this ticker has been less accurate, making the overall track record mixed.

Director Jerrold B Grossman purchases 12,500 ADMA shares at $8.01 as stock trades well below 52-week highs amid broad decline.

Jerrold B Grossman, a director of ADMA Biologics, purchased a substantial position of 12,500 shares at prices near the 52-week low, following a sharp stock decline. This marks his second open-market purchase in the past three years, adding to prior buying activity. The timing is contrarian—he is buying into weakness at a point where the stock has fallen sharply from its 52-week high. However, his track record offers a cautionary note: his most recent prior sale in this stock was poorly timed, as the stock rose significantly afterward, suggesting limited accuracy in read ng the company's trajectory. ADMA remains a profitable company with growing revenue, yet the director's purchase arrives during an extended pullback, buying shares at depressed levels rather than at prior peaks.